Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;398(6):6561-6577.
doi: 10.1007/s00210-025-03796-7. Epub 2025 Jan 28.

Effectiveness and safety of the use of sodium nitrite in patients with hypertension and pulmonary hypertension: a scoping review

Affiliations

Effectiveness and safety of the use of sodium nitrite in patients with hypertension and pulmonary hypertension: a scoping review

Jéssyca Milene Ribeiro et al. Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun.

Abstract

Evidence suggests that sodium nitrite may be effective in the treatment of hypertension and pulmonary hypertension. However, its use remains debated due to safety concerns. In response, a scoping review was conducted to map current knowledge on the efficacy and safety of sodium nitrite in patients with hypertension or pulmonary hypertension, addressing the question: What evidence supports the effectiveness and safety of using sodium nitrite in these patients? The databases MEDLINE (PubMed), EMBASE, Scopus, Web of Science, and LILACS were searched for clinical studies on hypertensive patients at any disease stage without restrictions on age, sex, ethnicity, publication date, or status. The primary outcomes analyzed were the efficacy and safety of sodium nitrite. A total of nine articles were included, eight from databases and one from gray literature. Sample sizes ranged from 5 to 36 patients, with sodium nitrite doses between 240 µg/kg/h and 325 mg. Five studies showed positive results for treating essential hypertension. Regarding safety, only one study raised concerns about adverse effects, probably due to the high dose that was used. In pulmonary hypertension patients classified as groups 2, 3, and 5, four studies suggested sodium nitrite was effective and safe, but it was ineffective in group 1. The studies included several significant limitations that should be considered. As such, the current evidence is insufficient to definitively confirm the efficacy and safety of sodium nitrite in hypertensive patients. Further research with larger sample sizes is necessary to obtain more conclusive results.

Keywords: Adverse effects; Clinical outcomes; Qualitative synthesis; Treatment effectiveness; Vasodilators.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

References

    1. Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M, Abdollahpour I, Abegaz KH, Abolhassani H, Aboyans V, Abreu LG, Abrigo MRM, Abualhasan A, Abu-Raddad LJ, Abushouk AI, Adabi M, Adekanmbi V, Adeoye AM, Adetokunboh OO,…, Murray CJL (2020) Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet 396(10258):1223–1249. https://doi.org/10.1016/S0140-6736(20)30752-2/ATTACHMENT/A535CF8F-9CAB-4...
    1. Alqarni AA, Aldhahir AM, Alghamdi SA, Alqahtani JS, Siraj RA, Alwafi H, AlGarni AA, Majrshi MS, Alshehri SM, Pang L (2023) Role of prostanoids, nitric oxide and endothelin pathways in pulmonary hypertension due to COPD. Front Med 10:1275684. https://doi.org/10.3389/FMED.2023.1275684 - DOI
    1. AtaeiAtaabadi E, Golshiri K, Jüttner A, Krenning G, Danser AHJ, Roks AJM (2020) Nitric oxide-cGMP signaling in hypertension: current and future options for pharmacotherapy. Hypertension 76(4):1055–1068. https://doi.org/10.1161/HYPERTENSIONAHA.120.15856/ASSET/BD7D1D58-76D6-4C... - DOI
    1. Bashline MJ, Bachman TN, Helbling NL, Nouraie M, Gladwin MT, Simon MA (2020) The effects of inhaled sodium nitrite on pulmonary vascular impedance in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. J Card Fail 26(8):654–661. https://doi.org/10.1016/j.cardfail.2020.04.006 - DOI - PubMed
    1. Benza RL, Simonneau G, Grünig E, Sandner P, Stasch JP (2024) The nitric oxide–soluble guanylate cyclase–cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase. Eur Respir Rev 33(171). https://doi.org/10.1183/16000617.0183-2023

Publication types

MeSH terms

LinkOut - more resources